USA flag logo/image

An Official Website of the United States Government

SBIR Phase II: In Vitro 3D Tissue Model for Toxicity Screening and Drug…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
1127551
Solicitation Year:
2011
Solicitation Topic Code:
Phase II
Solicitation Number:
Small Business Information
n3D
7000 Fannin Street suite 2140 Houston, TX 77030-3875
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2011
Title: SBIR Phase II: In Vitro 3D Tissue Model for Toxicity Screening and Drug Discovery
Agency: NSF
Contract: 1127551
Award Amount: $500,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase II project will use in vitro three-dimensional (3D) cell culturing enabled by the magnetic levitation method (MLM) as an improved tool for toxicity testing. This work will probe the effects of common agents on the lung, liver and kidney, three organs that play a central role in drug metabolism and are predisposed to toxic injury. 2D cell culture, commonly utilized for testing the cytotoxic effects of drugs, displays limited accuracy in predicting toxicity in vivo due to fundamental differences in the cellular microenvironment. While better representations of the 3D architecture of in vivo tissue are provided by animal models, they fail to accurately reflect whether or not drugs will cause cellular damage in humans as a result of biological differences between species. Our preliminary data shows that magnetic levitation maintains cells in culture in an arrangement that allows the cells to develop and communicate in a manner that is much closer to the in vivo environment than other in vitro systems. The broader impacts of this research are to improve assessment of drug toxicity and chemical hazards, reduce the use of animals, and advance the fields of in vitro toxicology testing and drug discovery. Commercial potential includes expansion of the device into high-throughput screening, generation of a prototype of a gas delivery system with capabilities to perform live cell microscopy, and development of a label-free viability assay for drug discovery and toxicity testing.

Principal Investigator:

Glauco R. Souza
8324728128
gsouza@n3dbio.com

Business Contact:

Glauco R. Souza
PhD
8324728128
gsouza@n3dbio.com
Small Business Information at Submission:

Nano3D Biosciences, Inc.
7000 Fannin Street suite 2140 Houston, TX 77030-3875

EIN/Tax ID: 263022209
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No